Investment agreement strengthens the strategic alliance between the two companies while supporting ITM in further developing its radiopharmaceutical pipeline and footprint in Asia Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s Targeted Radionuclide Therapeutic and Diagnostic candidates for Greater China ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Grand Pharmaceutical Group Limited (GP), a diversified global pharmaceutical company listed in Hong Kong, today announced...